New KDIGO blood pressure targets affect more than 10% of patients with CKD

The expanded indication for BP-lowering treatment by the 2021 Kidney Disease: Improving Global Outcomes guideline affects more than 10% of patients with chronic kidney disease, who are at higher CVD risk than those with well-controlled BP.
In an analysis of Korea National Health and Nutrition Examination Survey data, researchers also found that 3% to 5% of patients with chronic kidney disease (CKD) are no longer provided any indication for antihypertensive therapy by the new guideline, “whose CVD risk seems equivocal at this stage.”
“Intensive BP control to a further lowered

The expanded indication for BP-lowering treatment by the 2021 Kidney Disease: Improving Global Outcomes guideline affects more than 10% of patients with chronic kidney disease, who are at higher CVD risk than those with well-controlled BP.
In an analysis of Korea National Health and Nutrition Examination Survey data, researchers also found that 3% to 5% of patients with chronic kidney disease (CKD) are no longer provided any indication for antihypertensive therapy by the new guideline, “whose CVD risk seems equivocal at this stage.”
“Intensive BP control to a further lowered